Alexion makes $500 million investment in new Irish site

12 May 2015
alexion-college-park-big

American pharma company Alexion Pharmaceuticals (Nasdaq: ALXN) is to construct a five-story laboratory, office, packaging and warehouse facility as part of a 450 million euros ($502 million) investment in a Dublin site.

The new center at College Park in Blanchardstown, Dublin, will be the company’s third facility in Ireland, along with the current office in Park West, Dublin, and the planned site in Athlone. It is expected to create 200 new jobs. Irish Prime Minister Enda Kenny joined Alexion’s senior management team for the announcement (pictured).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical